We have studied the neuromuscular effects of mivacurium and changes in heart rate and arterial pressure in 40 elderly (aged 70 yr) and 20 young adult (aged 18-40yr) patients anaesthetized with thiopentone, fentanyl, nitrous oxide in oxygen and halothane. Neuromuscular block was monitored by train-of-four (TOF) stimulation of the ulnar nerve and recording of the force of contraction of the adductor pollicis muscle using a force displacement transducer and a neuromuscular function analyser (Myograph 2000, Biometer Ltd). Twenty elderly and 10 young adults received single closes of mivacurium 0.15 mg kg" 1 and spontaneous recovery was recorded. The other 20 elderly and 10 adults received the same dose but an infusion was started at T1 (first response in TOF) of 10% and the block maintained at this level. Haemodynamic effects were studied after administration of mivacurium over 15 or 5 s in elderly (n = 10 each) and over 5 s in adult (n = 10) patients. Onset of maximum block occurred at a mean time of 122 (SD 32) and 125 (49) s in elderly and young adults, respectively. Recovery of T1 to 25% occurred in 22.0 (5.7) and 17.2 (4.4) min, and T1 to 90% in 32.8 (6.9) and 24.4 (5.8) min in elderly and adult subjects, respectively. Recovery of the TOF ratio to 0.7 occurred in 32.8 (7.1) and 26.0 (15.0) min in the elderly and young subjects, respectively (all P < 0.05 between young and elderly). Mean mivacurium requirements by continuous infusion for maintenance of 90% block were 3.67 and 5.50 ug kg" 1 min" 1 in elderly and the young adults, respectively (P<0.05). In the elderly, neuromuscular effects were prolonged by approximately 30% and infusion requirements reduced by 38%. Residual neuromuscular block was antagonized easily with edrophonium or neostigmine. Except for small changes in systolic arterial pressure, mivacurium exhibited good haemodynamic stability in both groups. Cutaneous flushing was observed in six elderly (1 5%) and six young adults (30% Mivacurium is a new non-depolarizing neuromuscular blocking agent with a bisquaternary benzylisoquinolinium structure resembling that of atracurium and doxacurium [1] . Dose-response studies have shown the potency of mivacurium, in terms of its ED,,, to be 0.06-0.08 mg kg" 1 [2, 3] . It has a short duration of action as a result of hydrolysis by plasma cholinesterase (PCHE) [2] . The rate of hydrolysis of mivacurium in vitro, catalysed by purified human PCHE, is 70-88 % of the rate of suxamethonium [4] . At equipotent doses, its duration of action is approximately twice that of suxamethonium and approximately 35-40% that of atracurium and vecuronium [5, 6] .
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Summary
We have studied the neuromuscular effects of mivacurium and changes in heart rate and arterial pressure in 40 elderly (aged 70 yr) and 20 young adult (aged 18-40yr) patients anaesthetized with thiopentone, fentanyl, nitrous oxide in oxygen and halothane. Neuromuscular block was monitored by train-of-four (TOF) stimulation of the ulnar nerve and recording of the force of contraction of the adductor pollicis muscle using a force displacement transducer and a neuromuscular function analyser (Myograph 2000, Biometer Ltd). Twenty elderly and 10 young adults received single closes of mivacurium 0.15 mg kg" 1 and spontaneous recovery was recorded. The other 20 elderly and 10 adults received the same dose but an infusion was started at T1 (first response in TOF) of 10% and the block maintained at this level. Haemodynamic effects were studied after administration of mivacurium over 15 or 5 s in elderly (n = 10 each) and over 5 s in adult (n = 10) patients. Onset of maximum block occurred at a mean time of 122 (SD 32) and 125 (49) s in elderly and young adults, respectively. Recovery of T1 to 25% occurred in 22.0 (5.7) and 17.2 (4.4) min, and T1 to 90% in 32.8 (6.9) and 24.4 (5.8) min in elderly and adult subjects, respectively. Recovery of the TOF ratio to 0.7 occurred in 32.8 (7.1) and 26.0 (15.0) min in the elderly and young subjects, respectively (all P < 0.05 between young and elderly). Mean mivacurium requirements by continuous infusion for maintenance of 90% block were 3.67 and 5.50 ug kg" 1 min" 1 in elderly and the young adults, respectively (P<0.05). In the elderly, neuromuscular effects were prolonged by approximately 30% and infusion requirements reduced by 38%. Residual neuromuscular block was antagonized easily with edrophonium or neostigmine. Except for small changes in systolic arterial pressure, mivacurium exhibited good haemodynamic stability in both groups. Cutaneous flushing was observed in six elderly (1 5%) and six young adults (30% Mivacurium is a new non-depolarizing neuromuscular blocking agent with a bisquaternary benzylisoquinolinium structure resembling that of atracurium and doxacurium [1] . Dose-response studies have shown the potency of mivacurium, in terms of its ED,,, to be 0.06-0.08 mg kg" 1 [2, 3] . It has a short duration of action as a result of hydrolysis by plasma cholinesterase (PCHE) [2] . The rate of hydrolysis of mivacurium in vitro, catalysed by purified human PCHE, is 70-88 % of the rate of suxamethonium [4] . At equipotent doses, its duration of action is approximately twice that of suxamethonium and approximately 35-40% that of atracurium and vecuronium [5, 6] .
Although there are studies in healthy adults on the use of mivacurium, data on its use in the elderly are limited [7] . The present study was carried out to assess the neuromuscular effects of mivacurium 0.15 mg kg" 1 in elderly patients. The requirements of mivacurium by infusion were also determined after a bolus dose. The results were compared with those in young adult patients.
Patients and methods
After approval of the University Medical Ethics Committee, we studied 40 elderly (aged > 70 yr) and 20 young adult (aged 18-^tO yr) patients with their written informed consent. Exclusion criteria included patients taking any medication known to interfere with neuromuscular blocking drugs, family history of malignant hyperthermia, history of asthma, drug or alcohol abuse, and those whose body weight was 20 % greater than or less than ideal weight for height.
The 40 elderly patients were allocated to two groups of 20 each for study of neuromuscular and haemodynamic effects. The group of 20 young adults was similarly allocated to two groups of 10 each for measurement of neuromuscular and haemodynamic effects. In each age group the neuromuscular parts of the study were conducted before the haemodynamic parts. After premedication with oral temazepam 10-20 mg, anaesthesia was induced with thiopentone 4-5 mg kg" 1 and fentanyl 1-3 ug kg" 1 and maintained with 67% nitrous oxide in oxygen and halothane. to 0.7% in the elderly and 1.0% in young adults. Additional increments of thiopentone and fentanyl were given as required. Ventilation was assisted to maintain an end-tidal carbon dioxide partial pressure of 4.7-5.8 kPa. Skin temperature over the adductor pollicis was maintained greater than 32 °C by wrapping the arm in cotton wool. The ulnar nerve was stimulated at the wrist using surface electrodes with supramaximal stimuli of 0.2-ms duration, in a train-of-four (TOF) mode, at 2 Hz every 12 s. The resultant force of contraction of the adductor pollicis muscle was measured using a force displacement transducer and a neuromuscular function analyser (Myograph 2000, Biometer Ltd, Denmark).
After stabilization of control responses, all patients received a bolus dose of mivacurium 0.15 mg kg"
The first 10 elderly patients in the haemodynamic part of the study received mivacurium over 15 s. Depending on the haemodynamic changes in these patients (a decrease in MAP of less than 30%), the remaining 10 patients in this group were scheduled to receive mivacurium over 15 or 5 s. All elderly patients in the neuromuscular part of the study were given mivacurium over 15 s. The 20 young adult patients were given mivacurium over 5 s. Haemodynamic measurements, including heart rate and non-invasive arterial pressure, were recorded immediately preceding mivacurium and at 1-min intervals for 5 min thereafter. In addition, continuous ECG, end-tidal carbon dioxide and oxygen saturation were measured routinely in all patients.
The "lag time" (time from end of injection of the neuromuscular blocker to the first measurable reduction in twitch height) and the time to maximum block (onset time) were recorded in all patients.
The patients in the neuromuscular part of the study were allowed to recover spontaneously after the initial dose of mivacurium, and the times to recovery of Tl to 5, 25, 75 and 90% of control and for recovery of the TOF ratio to 0.7 were recorded. Patients were assessed in the recovery ward for any signs of recurarization by clinical criteria. The recovery index (time for recovery of Tl from 25 to 75 %) was calculated from the data obtained.
The 20 elderly and 10 young adult patients in the haemodynamic part of the study were allowed to recover spontaneously to Tl of 10 %. At this stage an infusion of mivacurium was started at an initial rate of 10 ug kg" 1 min" ). Neuromuscular data were analysed using t tests. Haemodynamic data were analysed by repeated measures analysis of variance.
Results
Patients in the various groups were comparable in height, weight and sex distribution (table 1) .
Lag and onset times of 44 and 122 s, respectively, in elderly patients were not significantly different from values of 43 and 125 s, respectively, in young adults (table 2) . Times to recovery to all end-points were significantly longer in the elderly (P < 0.05). Times to recovery of Tl to 25 % of control (duration of clinical block) and to a TOF ratio of 0.7 (full recovery) were 22 and 32.8 min in the elderly and 17.2 and 26 min in young adults. The recovery index differed between the two groups by 2.3 min (P < 0.05).
There were no significant alterations in haemodynamic data in those elderly patients who received mivacurium over 15 s (table 3) . The other group of 10 elderly patients therefore received mivacurium over 5 s. This group and the group of young adults who received mivacurium over 5 s had a small but statistically significant (P < 0.05) decrease in systolic arterial pressure at 2-5 min after administration of the neuromuscular blocker. However, the changes in arterial pressure were relatively small and of little clinical significance. There were no significant changes in heart rate in any of the three groups. Cutaneous flushing was observed in six (15%) elderly and six (30 %) adult patients after bolus dose administration of mivacurium. This was not accompanied by any clinically important haemodynamic changes.
Mean duration of infusion in elderly patients was 93 (range 30-190) min and in young adults 67.1 (40-90) min ( fig. 1 ). Mean infusion requirement in elderly patients was 3.67 (1.0-7.4) ug kg" 1 min" 1 and in young adults 5.5 (3.5-7.4) ugkg" 1 min" 1 . The steady state infusion rates were achieved over 7-15 min. The differences between the two groups in mean mivacurium requirements and at each time from 10 min onwards were significant (P < 0.05). Although there were large individual variations in infusion requirements, these were relatively constant in each patient as shown by the small change in mean mivacurium requirements after initial stabilization. Figure 1 Mean (SD) infusion requirements of mivacurium in elderly (#) and young adult (O) subjects. The difference between the groups was significant at all times from 10 min onwards.
The results of the recovery times after antagonism in the 20 elderly patients who received infusions are shown in table 4. Onset of action was significantly faster (P < 0.01) with edrophonium as shown by the more rapid return of Tl to 25% in this group but there were no significant differences in the times taken for Tl to reach 90 % of control or for the TOF ratio to reach 0.7. A TOF ratio of 0.7 was attained in British Journal of Anaesthesia 7.0 (3.5)+ approximately 7 min. One patient given edrophonium did not attain a TOF ratio of 0.7. However, this patient showed adequate signs of clinical recovery and his trachea was extubated on clinical grounds. None of the patients had any signs of recurarization in the recovery room.
Discussion
We found that the duration of action of mivacurium in healthy adult patients was approximately twice that of suxamethonium and about half that of equipotent doses of atracurium and vecuronium. This relatively short duration of action is attributed primarily to rapid hydrolysis by PCHE [2, 4] . Because of its short duration of action, lack of cumulative effects and rapid recovery, it is a suitable agent for administration by infusion [8] .
The duration of action of mivacurium in the present study was prolonged in the elderly by approximately 30 % and infusion requirements were lower by a similar amount compared with young adults. A recent report has shown that PCHE activity is significantly lower in elderly compared with adults although it is still well within the normal range [9] . It has also been shown that there is an inverse relationship between PCHE activity and duration of action of mivacurium [10, 11] . A decrease in PCHE activity may therefore be the reason for the longer duration of action of mivacurium in the elderly. A reduction of this extent in PCHE activity in those with phenotypically normal enzyme is, however, not Table 3 Mean (SD) changes in systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressures and heart rate (HR) in the elderly and young adults given mivacurium over + 15 s or + 5 s. * P < 0.05 compared with 0 min usually associated with prolongation of the effect of suxamethonium; the enzyme activity needs to be reduced by nearly 70% for such an effect to occur [12, 13] . However, it is possible that metabolism of mivacurium is affected much more than that of suxamethonium, even with smaller decreases in PCHE activity. The possibility of differences in the pharmacokinetics of mivacurium between elderly and adult subjects may also need to be considered and examined in detail, particularly with reference to its three isomers. The results of the present study contrast with those of Basta and colleagues who observed no prolongation of the effect of mivacurium in the elderly [7] . However, they were using a dose of only 0.1 mg kg" 1 of mivacurium during isofiurane anaesthesia and involved only nine patients. The spontaneous recovery variables observed in the young patients in the present study were similar to those observed in a previous study [6] .
Mean infusion requirements in the elderly and young adults were 3.67 and 5.5 ug kg" 1 min" 1 , respectively. The differences between the groups were significant (P < 0.05). The infusion rates required in the young adults in the present study were somewhat lower than those observed by others [14] [15] [16] [17] [18] . However, in some of these studies, the authors were not using volatile anaesthetics and neuromuscular block was maintained at 90-95 % of control compared with 90% block in the present study. The reduced infusion requirements seen in the elderly are probably related to the somewhat longer duration of action of mivacurium in this age group as seen after single doses in the present study. It has been shown that the infusion requirements of mivacurium are also dependent on PCHE activity [5, 19] . In phenotypically normal patients, an inverse relationship was found to exist between PCHE activity and time to recovery of the first response in the TOF after mivacurium 0.2 mg kg" 1 [19] . As mivacurium is metabolized by PCHE, and neostigmine is known to inhibit PCHE [20] , it was considered interesting to examine if antagonism with edrophonium would be any better. Although antagonism with edrophonium showed a more rapid initial effect, the other recovery indices were similar with the two anticholinesterases. The recovery times in the elderly patients after antagonism with edrophonium or neostigmine were also comparable with other studies in adult patients [14, 15, 18] . The recovery times of about 4.5 min after antagonism with edrophonium or neostigmine at the end of infusion were only about 3.5 min shorter than those observed after spontaneous recovery with a single dose in the same age group of patients, indicating easy antagonism of mivacurium.
Benzylisoquinolinium neuromuscular blocking drugs have the potential to release histamine [21, 22] . In the present study, administration of mivacurium over 15 s in elderly patients was not associated with any significant changes in arterial pressure or heart rate. However, administering the same dose over 5 s was associated with small (7%) but statistically significant decreases in systolic arterial pressure at 2-5 min after mivacurium in both young adults and the elderly. However, none of the patients in this study had decreases in arterial pressure below clinically acceptable levels. We chose a dose of 0.15 mg kg" 1 as previous studies have shown that doses of 0.2 mg kg" 1 or higher, when given rapidly, are associated with significant hypotension [23, 24] . Cutaneous flushing was observed in six (15%) elderly and six (15 %) young patients. However, this was not accompanied by any significant cardiovascular effects.
